Patents Assigned to Biotechnologicky Ustav Av Cr. V.V.I.
-
Publication number: 20230044560Abstract: A method of separation of sperm cells with undamaged intact heads from sperm cells with damaged heads and/or somatic cells and/or cell debris in a sperm sample obtained from a human, comprising the steps of: providing an anti-CD46 antibody or CD46-binding ligand bound to a carrier and/or to a tag; contacting the sperm sample with the anti-CD46 antibody or CD46 -binding ligand bound to the carrier and/or to the tag in order to bind CD46 presenting cells and/or cell debris from the sperm sample to the anti-CD46 antibody or CD46-binding ligand; removing the CD46 presenting cells bound via the anti-CD46 antibody or CD46 -binding ligand to the carrier and/or to the tag to obtain a sperm sample free of CD46 presenting cells, wherein CD46 presenting cells include sperm cells with damaged heads, somatic cells and cell debris, is disclosed.Type: ApplicationFiled: January 17, 2021Publication date: February 9, 2023Applicants: BIOTECHNOLOGICKY USTAV AV CR, V. V. I., PRIMECELL BIOSCIENCE, A.S., CESKA ZEMEDELSKA UNIVERZITA V PRAZEInventors: Katerina KOMRSKOVA, Pavla POSTLEROVA, Michaela FROLIKOV A, Serhiy FOROSTYAK, Ondrej SIMONIK
-
Publication number: 20200078379Abstract: The deferoxamine derivatives of general formula I and pharmaceutically acceptable salts thereof, at least one of R1 and R2 is a substituent of formula II. The novel derivatives are particularly suitable as medicaments, preferably for the treatment of cancer. Pharmaceutical preparations of compounds of formula I and a metal, preferably gallium, are also provided resulting in even more active medicaments or contrast agents. Combinations with other agents, resulting in synergistic effects are provided.Type: ApplicationFiled: July 13, 2018Publication date: March 12, 2020Applicants: BIOTECHNOLOGICKY USTAV AV CR, V.V.I, SMART BRAIN S.R.O.Inventors: JAROSLAV TRUKSA, Lukas WERNER, Jan STURSA
-
Publication number: 20200038523Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.Type: ApplicationFiled: July 17, 2019Publication date: February 6, 2020Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
-
Patent number: 10406247Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.Type: GrantFiled: July 6, 2016Date of Patent: September 10, 2019Assignees: Technische Universität München, Biotechnologicky Ustav AV CR, v.v.i.Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
-
Publication number: 20180318451Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.Type: ApplicationFiled: July 6, 2016Publication date: November 8, 2018Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.Inventors: Arne SKERRA, Antonia RICHTER, Volker MORATH, Cyril BARINKA, Jakub PTACEK
-
Patent number: 9896466Abstract: The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.Type: GrantFiled: April 7, 2014Date of Patent: February 20, 2018Assignees: KKCG AG, Biotechnologicky Ustav Av Cr. V.V.I., Smart Brain S.R.O.Inventors: Jiri Neuzil, Jan Stursa, Lukas Werner